Breast tumor kinase (Brk) is a nonreceptor tyrosine kinase that is overexpressed in a high percentage of breast carcinomas. Brk contains SH3, SH2, and tyrosine kinase catalytic domains in a similar arrangement as Src family kinases. In this study, we explored the roles of the SH3 and SH2 domains in Brk regulation and substrate binding. We introduced a series of mutations into Brk that were predicted to disrupt the intramolecular interactions involving the SH3 and SH2 domains. These mutant forms of Brk displayed higher activity than wild-type Brk when expressed in human embryonic kidney HEK293 cells. These studies also allowed us to pinpoint the intramolecular binding site for the SH3 domain. To examine substrate binding, we compared binding and phosphorylation of Sam68, a physiological substrate of Brk. These experiments showed that the SH3 domain plays a particularly important role in substrate recognition. We confirmed this conclusion using a series of synthetic peptides in which a substrate sequence was coupled to an SH3 or SH2 ligand. The SH3-binding substrate had a significantly lower K m than a control, while no difference was observed between an SH2-binding substrate and a control. Taken together, our data suggest that SH3 interactions will govern phosphorylation of many substrates by Brk.
Introduction
The nonreceptor tyrosine kinase Brk (breast tumor kinase) was cloned from a human metastatic breast tumor (Mitchell et al., 1994) . Brk is a member of the Frk family of tyrosine kinases. Brk is overexpressed in many breast carcinomas, metastatic melanomas, and colon tumors (Mitchell et al., 1994; Barker et al., 1997; Easty et al., 1997; Llor et al., 1999; Serfas and Tyner, 2003) . In normal tissues, expression of Brk (or of Sik, the mouse ortholog) is only detected in differentiating epithelial cells of the skin and gastrointestinal tract (Vasioukhin et al., 1995; Llor et al., 1999) . In mammalian cell lines, Brk overexpression can partially transform fibroblasts and sensitize epithelial cells to epidermal growth factor (EGF). A constitutive interaction between Brk and EGF receptor was also observed in these cells (Kamalati et al., 1996) . In mammary epithelial cells, expression of Brk resulted in enhanced EGF-stimulated ErbB3 phosphorylation, as well as increased recruitment of phosphoinositide 3-kinase and Akt activation (Kamalati et al., 2000) . In T-47D breast carcinoma cells that overexpress Brk, suppression of Brk expression by RNA interference inhibited cell proliferation (Harvey and Crompton, 2003) . Brk is localized to the nuclei of normal prostate epithelial cells, and a correlation was observed between decreased nuclear localization and increased tumorigenicity in prostate tumors and prostate cancer cell lines (Derry et al., 2003) . All of these findings suggest that deregulation of Brk expression, activity, or localization may result in aberrant cell growth and development of cancer.
Brk possesses SH3, SH2, and kinase catalytic domains in a similar arrangement to that of Src family kinases (Mitchell et al., 1994; Serfas and Tyner, 2003) . Src kinase activity is negatively regulated by intramolecular interactions between the SH2 and SH3 domains and their ligands Sicheri and Kuriyan, 1997; Sicheri et al., 1997; Xu et al., 1997) . The SH2 domain binds to a phosphorylated tyrosine residue (Tyr527) near the C-terminus, and the SH3 domain binds to the proline-rich linker region between the SH2 and kinase domain . Src family kinases can be activated by disruption of the intramolecular interactions using high-affinity exogenous SH2/SH3 ligands (Liu et al., 1993; Alexandropoulos and Baltimore, 1996; Briggs et al., 1997; Moarefi et al., 1997) .
In a previous study using purified Brk, we showed that Brk is regulated by autophosphorylation at Tyr342 and by intramolecular interactions involving the SH3 and SH2 domains (Qiu and Miller, 2002) . Mutation of the C-terminal tyrosine 447, which is analogous to Y527 in Src, increased the activity of Brk towards cellular substrates and synthetic peptide substrates. This mutant also had higher SH2 accessibility than that of wild-type Brk, suggesting that the SH2 domain is normally involved in an autoinhibitory interaction with the C-terminus. The activation of Brk by a proline-rich peptide indicated the existence of an autoinhibitory interaction involving the SH3 domain. The intramolecular binding site for the SH3 domain was not identified.
The SH2 and SH3 domains of Src family kinases (and other nonreceptor tyrosine kinases) also bind to substrates, thus providing specificity and increasing the signaling efficiency Brown and Cooper, 1996) . These intermolecular interactions also regulate the subcellular localization of the kinases. Thus, Src kinases carrying SH2/SH3 mutations with ligandbinding defects have impaired transforming ability (Jove and Hanafusa, 1987; Erpel et al., 1995; Tian and Martin, 1997) . Replacement of the Abl SH2 domain with other SH2 domains leads to a change of substrate specificity (Mayer and Baltimore, 1994) . Studies with synthetic peptide substrates have shown that the presence of an SH2 or SH3 ligand in the peptide enhances phosphorylation by Src (Pellicena et al., 1998; Scott and Miller, 2000) . Binding of the ligand to the SH2/SH3 domains activates the kinase by replacing the intramolecular interaction, and increases the effective substrate concentration by tethering the substrate to the kinase (Nguyen and Lim, 1997; Pawson et al., 2001; Miller, 2003) .
Very little is known about substrate recognition by Brk and related kinases. The two physiological substrates for Brk that have been identified are Sam68 (Derry et al., 2000) and BKS (Mitchell et al., 2000) . Sam68, a nuclear RNA-binding protein, was originally identified as a target for Src in mitosis (Fumagalli et al., 1994; Taylor and Shalloway, 1994) . Binding and phosphorylation of Sam68 involves both the SH3 and the SH2 domain of Brk (Derry et al., 2000) . Phosphorylation of Sam68 by Brk was recently shown to decrease the ability of Sam68 to enhance the function of the Mason-Pfizer monkey virus constitutive transport element (Coyle et al., 2003) . BKS is an adaptor-like protein. Neither the SH3 domain nor the SH2 domain of Brk was essential for BKS binding. An SH2-like domain in BKS, and Brk kinase activity were found to be required for the Brk-BKS interaction (Mitchell et al., 2000) .
In this study, we generated a series of Brk mutants to study kinase regulation and substrate recognition. We examined substrate binding and phosphorylation using both mammalian cell expression and synthetic peptide systems. We identified a potential intramolecular ligand for the SH3 domain, and found differences between Brk and Src in SH3-dependent regulation. Our main conclusion is that both SH2 and SH3 domains are involved in autoinhibition, while the SH3 domain of Brk appears to be the major substrate-targeting domain.
Results
We constructed a series of Brk mutants to examine the importance of the SH3 and SH2 domains in enzyme regulation and substrate recognition (summarized in Figure 1 ). Several of the mutants were designed to disrupt Brk autoinhibition. Trp44 is a conserved residue in the SH3 domain that makes contacts with prolinerich ligands. We produced a W44A mutant to examine the importance of this residue. We also studied a BrkY447F mutant with a substitution in the C-terminal tyrosine. We previously purified this mutant and showed that Y447F Brk has a higher activity than wild type (Qiu and Miller, 2002) , and Y447F has been used as an activated variant in cellular studies (Serfas and Tyner, 2003) . We constructed a W184A mutant because W184 is analogous to W260 (in Src kinases), which is required for the interaction between the SH3 and the linker region. SH3-dependent inhibition is lost in the W260A mutant form of the Src kinase Hck (LaFevre-Bernt et al., 1998) . Although the intramolecular binding site for the SH3 domain has not been identified in Brk, a prolinerich segment exists between the SH2 and catalytic domains that could potentially serve this function. To test this possibility, we generated a 3PA mutant, in which three prolines (P175, P177, P179) in the putative linker were substituted with alanines. Our expectation was that all of these mutants would show higher activity than wild-type Brk because the intramolecular interactions were disrupted.
We also created mutants with larger deletions to test the involvement of these regions in substrate binding. The DSH2 and DSH3 mutants have complete deletions in these domains. Brk has a shorter N-terminus than Src family kinases, and Brk lacks an acylation site (Mitchell et al., 1994; Serfas and Tyner, 2003) . An N-terminal deletion mutant (Ndel) was created to examine the possible functions of the N-terminus in Brk. Finally, we tested K219M and Y342A mutants as negative controls. K219M is a kinase-inactive Brk mutant with a substitution in the ATP-binding site (Derry et al., 2000; Kamalati et al., 1996) . We previously showed that Y342 is the major autophosphorylation site in Brk, and that the Y342A mutant has dramatically reduced Brk activity (Qiu and Miller, 2002) .
To test the overall activity of these mutants, we expressed wild-type and mutant forms of Brk in HEK293 cells. To measure kinase activity, we examined phosphotyrosine-containing proteins in equal amounts of cell lysates using anti-pTyr Western blotting ( Figure 2a ). The mutants were expressed at similar levels to wild type ( Figure 2b ). Consistent with our previous results (Qiu and Miller, 2002) , the K219M and Y342A mutants displayed much lower activity than wild-type Brk. The Y447F and W44A mutants showed enhanced phosphorylation of cellular proteins compared to wild-type Brk, as did the DSH2, DSH3, and 3PA mutants. Of all the proteins examined, the Y447F and DSH2 forms of Brk gave the highest levels of substrate phosphorylation, suggesting that the putative SH2-pY447 interaction is most important in maintaining the inactive conformation. The Ndel mutant had roughly the same activity as wild-type Brk. Finally, contrary to the expectations based on Src, the W184A Brk mutant showed lower kinase activity ( Figure 2a ).
The results presented in Figure 2 were from assays in whole-cell lysates. These results could reflect changes in kinase activity and/or substrate recognition. To distinguish these effects, we first determined the tyrosine kinase activity by assaying Brk autophosphorylation. We immunoprecipitated Brk (wild type or mutants) from HEK293 cells and performed a Western blot with anti-pTyr antibody (Figure 3a) . The K219M and Y342A mutants showed dramatically reduced autophosphorylation, as expected. These results make it unlikely that another kinase phosphorylates Brk in this experiment. Consistent with the results from Figure 2 , we observed higher autophosphorylation activity in the five activated mutants: Y447F, DSH2, DSH3, 3PA, and W44A. These results suggest that Brk normally exists in an autoinhibited conformation, with the SH2 domain binding to the phosphorylated C-terminus and the SH3 domain binding to a linker segment containing residues P175, P177, and P179. The Ndel mutant had similar autophosphorylation activity as wild-type Brk, suggesting that this region is not involved in kinase regulation. The W184A mutant displayed dramatically reduced autophosphorylation, indicating that this mutation resulted in the loss of kinase activity.
Sam68 is a Brk substrate that interacts with the Brk SH2 and SH3 domains (Derry et al., 2000) . As a model for SH3/SH2-dependent substrate binding, we examined the interaction between Sam68 and the various forms of Brk by coimmunoprecipitation analysis (Figure 4a ). There are similar amounts of Sam68 present in the WT, K219M, and Y342A immunoprecipitations, indicating that Brk activity is not essential for Sam68 binding. Ndel and wild-type Brk had similar levels of Sam68 binding. The SH3 domain mutants (DSH3 and W44A) (Figure 5a ). As in whole-cell lysates (Figure 2 ), almost no Sam68 phosphorylation was detected from cells expressing the K219M or Y342A mutants. Wild-type Brk and the N-terminal deletion mutant showed similar Sam68 phosphorylation. The Y447F, DSH2, and 3PA mutants gave higher levels of Sam68 phosphorylation than wild type, consistent with the results presented in Figure 2 from whole-cell lysates. We observed similar or less Sam68 phosphorylation in cells expressing the DSH3 and W44A mutants, while the W184A mutant gave no Sam68 phosphorylation, consistent with its lowered kinase activity (Figure 2 ).
Brk and Sam68 are localized both to the cytoplasm and to the nucleus (Serfas and Tyner, 2003) , and Brk has previously been shown to phosphorylate Sam68 in the nucleus (Derry et al., 2000) . We carried out subcellular fractionations to eliminate the possibility that some effects on Sam68 binding and phosphorylation could be due to improper localization of the mutants. As shown in Figure 6 , Brk overexpressed in HEK293 cells localizes to both the nucleus and cytoplasm. Wild-type Brk and all mutants had similar patterns of localization. We detected Sam68 mainly in the nuclear fraction from cells expressing wild-type or mutant forms of Brk (Figure 6b) . Thus, the various forms of Brk are equally available for Sam68 binding under these conditions.
From the experiments in HEK293 cells, we hypothesize that both the SH2 and SH3 domains of Brk are involved in autoinhibition, but that the SH3 domain plays a more important role in targeting substrates. To test this hypothesis, we synthesized peptides containing SH2 or SH3 ligands (Table 1 ). The sequences of the ligands (pYEEY for the SH2 domain and GAAPPPPPVPRGR for the SH3 domain) are derived from the sequence of Sam68. To confirm that these ligands can bind to Brk protein, we immobilized the peptides and performed a peptide-binding assay with purified Brk. These experiments confirmed that Brk binds to the peptides (Figure 7) . The pYEEY sequence bound more efficiently to Brk than a peptide with the pYEEI sequence that binds best to Src family kinases (Figure 7a) . Binding of the pYEEY SH2 ligand to purified Brk led to an approx. twofold increase in kinase activity, with a K act of approximately 300 mM (Figure 7b) .
Next, we incorporated these ligands into synthetic peptide substrates (Table 1) . We also generated control peptides in which key binding features were eliminated (pTyr changed to Phe in the case of the SH2 peptide, or Pro residues changed to Ala in the case of the SH3 peptide). The substrate sequence used here (EEEIY-GEF) is derived from a peptide library study of Src specificity (Songyang et al., 1995) ; we previously showed that this sequence is phosphorylated efficiently by Brk (Qiu and Miller, 2002) . We designed the spacer length between the ligand and substrate sequences based on our previous results for Src (Pellicena et al., 1998) . We carried out steady-state kinetic measurements with the peptide substrates using a continuous spectrophotometric assay for Brk (Table 2) (Barker et al., 1995; Qiu and Miller, 2002) . The SH3-binding substrate had a K m of 35 mM, approximately sevenfold lower than the SH3 control substrate. Values of V max for the two peptides were similar. In contrast, the SH2-binding substrate and its control showed very similar values for K m . The V max for the substrate peptide was approximately 1.7-fold higher than the control, consistent with the observation that the pYEEY peptide activates Brk. Thus, the synthetic peptide studies showed that incorporation of an SH3 ligand (but not an SH2 ligand) into a substrate sequence resulted in a significant decrease in peptide K m . These results are consistent with an important role for the SH3 domain in substrate binding.
Discussion
Although the three-dimensional structure of Brk has not been determined, the mechanisms for Brk regulation appear to be similar to those that regulate Src family kinases. As is the case for Src, disruption of an intramolecular SH3 interaction activates Brk (e.g. the W44A and3PA mutants shown in Figures 2 and 3) . Like The activity of purified Brk was measured in the presence of varying concentrations of pYEEY peptide. Brk activity was measured using the coupled spectrophotometric assay.
The assay was performed with 1 mm Brk and 500 mm substrate peptide. V a is the velocity measured in the presence of pYEEY peptide minus the velocity measured in its absence The kinetic parameters for peptides were determined by the spectrophotometric assay. Peptide concentrations were varied from 0.25 K m to 4 K m for the determinations. The assays were carried out at 1 mM enzyme and 500 mM ATP
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Src, purified Brk can be activated by addition of an exogenous ligand for the SH3 domain (Qiu and Miller, 2002) . Mutation of three proline residues in the region between the SH2 and catalytic domains of Brk activates the enzyme (Figure 2 ) and increases the accessibility of the SH3 domain (Figure 4 ). These results suggest that the linker containing Pro 175, Pro177, and Pro179 functions as the intramolecular ligand for the Brk SH3 domain. Brk also appears to be regulated by an intramolecular interaction involving the SH2 domain and phosphorylated Tyr447. When expressed in 293 cells, the Y447F and DSH2 mutants have increased activity (Figures 2,3) . We also observed approximately twofold activation of purified Brk by a synthetic peptide containing the pYEEY sequence. A possible explanation for this relatively low level of activation is that the Spodoptera frugiperda (Sf9)-expressed Brk might not be in a completely downregulated form. We attempted to produce downregulated Brk by coexpressing Csk and Brk in Sf9 cells. However, the coexpressed Brk had a similar phosphorylation status and kinase activity to Brk expressed alone (HQ and WTM, unpublished observations). We also attempted to engineer a Csk recognition sequence by introducing the sequence ExQY (Wang et al., 2001) into the Brk C-terminus and coexpressing with Csk in Sf9 cells. Again, no differences were observed between wild-type Brk and the mutant. The question of how highly phosphorylated the C-terminus of Brk is in mammalian cells, and how tightly it is associated with the SH2 domain, will require further study.
The N-terminal region of the nonreceptor tyrosine kinase Abl has recently been shown to play a critical role in enzyme regulation Nagar et al., 2003) . To test whether the N-terminal sequence of Brk plays an analogous role, we produced an Nterminal deletion mutant. We observed no difference between the N-terminal deletion mutant and wild-type Brk with respect to enzyme activity or Sam68 binding (Figures 2-4) . Thus, the N-terminus of Brk is unlikely to play an important role in these functions of Brk.
In Src family kinases, Trp260 is within the SH2-kinase linker and plays an important role in maintaining the interactions of the SH2 and SH3 domains with their intramolecular ligands (LaFevre-Bernt et al., 1998) . In Hck, a W260A mutation increased basal activity and the accessibility of the SH2 and SH3 domains (LaFevreBernt et al., 1998) . The analogous W184A mutation in Brk increased the accessibility of the SH3 domain, as detected by increased Sam68 binding (Figure 4b ). This is consistent with the location of W184 near the critical proline residues in the linker (P175, P177, and P179). Thus, the W184A mutation appears to have destabilized the SH3-linker interaction. In contrast to the activating effect of the W260A mutation in Hck, the W184A mutation abolished Brk kinase activity (Figures 2 and  3) . A similar result was reported for c-Raf; the analogous W342A mutation led to the loss of c-Raf kinase activity, although the enzyme retained its capacity to bind substrates (McPherson et al., 2000) . The sequences surrounding the conserved Trp residue differ between Src, Brk, and c-Raf, suggesting that the modes of regulation might also differ. In the crystal structure of inactive Hck , W260 points into a hydrophobic region of the N-terminal lobe of the catalytic domain and interacts with the aC helix, thus keeping the kinase in an inactive conformation. Our data suggest that W184 of Brk interacts differently with the catalytic domain and stabilizes the active conformation of the kinase.
Sam68 is a known physiological substrate of Brk (Derry et al., 2000) . We found that the SH3 domain of Brk is critical for binding endogenous Sam68. Thus, the DSH3 mutant showed a reduced level of Sam68 binding (Figure 4 ). Sam68 also bound very weakly to a mutant in which a binding determinant for proline-rich peptides (W44) was mutated. In the W184A and 3PA mutants, the intramolecular SH3 interaction is presumably disrupted, freeing the SH3 domain to interact with other partners. These mutants showed an increased level of Sam68 binding (Figure 4) . With regard to Sam68 phosphorylation ( Figure 5 ), one result that does not seem to fit this model is that the DSH3 mutant showed comparable phosphorylation to wild-type Brk. One possible explanation is that the increased kinase activity of this mutant, combined with a weak, transient interaction with Sam68, is sufficient to drive Sam68 phosphorylation.
The SH2 domain of Brk is clearly dispensable for Sam68 binding, as the DSH2 mutant showed increased Sam68 binding relative to wild-type Brk (Figure 4) . We speculate that the increased binding seen in this mutant is because a deletion of the SH2 domain also destabilizes the intramolecular SH3 interaction. This is consistent with expectations based on Src kinases, where the intramolecular SH3 and SH2 interactions are mutually dependent (LaFevre-Bernt et al., 1998; Young et al., 2001) . By the same reasoning, the Y447F mutant would have both SH2 and SH3 domains available for interactions with substrates, explaining the increased Sam68 binding by this mutant (Figure 4) . Our results are consistent with those reported by Derry et al., in which Sam68 was shown to interact with GSTSik-SH3, but only weakly with GST-Sik-SH2 (Derry et al., 2000) .
It is important to note that Brk may interact with other proteins by different mechanisms. For example, the W44A mutant form of Brk showed reduced binding to the adaptor protein BKS compared to wild-type Brk, but binding was not abolished altogether (Mitchell et al., 2000) . In contrast, binding between Brk and BKS depended critically on the kinase domain of Brk and the SH2-like domain in BKS. These results suggest that phosphotyrosine-containing motifs in Brk are the primary determinants for BKS binding and phosphorylation.
Our synthetic peptide experiments also focused on the functions of SH2 and SH3 domain in Brk substrate phosphorylation. We previously showed that introducing Src SH2 or SH3 ligands into substrate peptides lowered the values of peptide K m (Pellicena et al., 1998; Scott and Miller, 2000) . For Brk, we found that the SH3 substrate peptide had a significantly lower K m than the SH3 control peptide, whereas the SH2 peptides had similar K m values (Table 2) . These results are consistent with those we obtained in our experiments in HEK293 cells, and suggest that the SH3 domain plays a particularly important role in Brk substrate recognition. The presence of an SH3 ligand in a potential protein substrate will cause the protein to bind Brk, raising the effective local concentration of the protein and driving phosphorylation by the catalytic domain.
Materials and methods

Brk constructs and mutagenesis
The baculovirus expression vector for Brk was described previously (Qiu and Miller, 2002) . For mammalian cell expression, the Brk coding sequence was amplified by PCR using oligonucleotides: 5-CGGAATTCAATGGTGTCCCG GGACCAGGCTCACCTG and 3-CGGGATCCTCAGGT CGGGTTCTCGTAGCTGGTGAAGCTG. The DNA was subcloned into the EcoRI and BamHI sites of plasmid p3XFLAG-CMV-7.1 (Sigma). To avoid any possible functional interference from the FLAG-tag, we deleted the 3 Â FLAG coding sequence in the vector. Site-directed mutagenesis was performed using the Stratagene QuikChange Kit following the manufacturer's protocol. Mutations were confirmed by DNA sequencing.
Protein expression and purification
His-tagged wild-type Brk was expressed in Sf9 cells and purified essentially as described previously (Qiu and Miller, 2002) , with the following modification: the cell lysate was first applied to a Source Q 15 column (Amersham), which had been equilibrated with buffer A (20 mM Tris pH 8.5, 10% glycerol, 5 mM b-mercaptoethanol) containing protease inhibitors (5 mg/l of aprotinin, 5 mg/l leupeptin, 0.1 mM PMSF), 0.1 mM vanadate, and 1 mM EDTA. The proteins were eluted with a linear gradient to 1 M NaCl in buffer A. The peak fractions (determined by Coomassie staining) were pooled and loaded onto an Ni-NTA column (Qiagen). Brk was eluted from the Ni-NTA column according to the earlier method (Qiu and Miller, 2002) .
Synthetic peptides
Peptides were synthesized on an Applied Biosystems automated 431A peptide synthesizer. The peptides were purified by reverse-phase high-pressure liquid chromatography and characterized by matrix-assisted laser desorption ionization (MALDI)-time of flight mass spectrometry.
Kinase assay
The Brk kinase activity assay was carried out as described previously (Qiu and Miller, 2002) . Briefly, the reactions were measured by a continuous spectrophotometric assay performed in 50 ml buffer containing 20 mM Tris (pH7.5), 3 mM MnCl 2 , 1 mM phosphoenolpyruvate, 0.28 mM NADH, 89 U/ml pyruvate kinase, and 124 U/ml lactate dehydrogenase. Initial rates were measured and fit to the Michaelis-Menten equation to determine the kinetic parameters.
Peptide binding assay
The pYEEI, pYEEY, and SH3 ligand peptides were immobilized on Affi-gel 15 (Bio-Rad) in 0.1 M MOPS buffer, pH 7.5. The peptide-bound resin was washed extensively with 0.1 M MOPS buffer and equilibrated with binding buffer (50 mM Tris, pH 7.5, 250 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 0.5 mM sodium vanadate, and 1 mM dithiothreitol). Brk protein (2 mg) was incubated with 30 ml resin in binding buffer for 30 min. The bound protein was eluted with SDS sample buffer and analysed by SDS-PAGE with anti-Brk Western blotting.
Mammalian cell expression and immunoprecipitation
The HEK293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum, 100 U/ml streptomycin sulfate, and 100 mg/ml amphotericin B. Transfections were carried out with MIRUS TransIT (Mirus Corp) using HEK293 cells that had been plated 24 h previously. The cells were harvested 48 h after transfection.
After washing with cold phosphate-buffered saline, the cells were lysed in lysis buffer (20 mM Tris, pH 7.5, 1 mM EDTA, 1% Nonidet P-40, 140 mM NaCl) with protease inhibitors (5 mg/l aprotinin, 5 mg/l leupeptin, 0.1 mM phenylmethylsulfonyl fluoride) at 41C for 30 min. The cell lysates were centrifuged at 14 000 g for 15 min at 41C. After protein concentration determination with the Bio-Rad protein assay, 1 mg/ml concentrations of the cell lysates were used for immunoprecipitation experiments. We first precleared the lysates with 1 mg rabbit or mouse IgG and 15 ml protein A beads (Sigma) for 1 h at 41C. The protein A beads were discarded after centrifugation. Next, 1 mg antibody and 15 ml protein A beads were added to the precleared cell lysates and incubated for 3 h at 41C. The beads were washed three times with lysis buffer, and immunoprecipitated proteins were resolved by SDS-PAGE. The proteins were transferred to PVDF membranes and immunoblotted with appropriate antibodies. The immunoreactive proteins were visualized using horseradish peroxidase-conjugated secondary antibody and an enhanced chemiluminescent (ECL) detection kit (Amersham Pharmacia Biotech).
Subcellular fractionation
Cells were harvested with ice-cold phosphate-buffered saline and resuspended in buffer A (10 mM HEPES, pH 7.0, 5 mM MgCl 2 , 25 mM KCl) with protease inhibitors (10 mM phenylmethylsulfonyl fluoride, 10 mg/l leupeptin, 10 mg/l aprotinin) at a density of 1 Â 10 7 cells/ml. The cells were forced through a 23-gauge needle 10 times and immediately mixed with an equal volume of buffer B (buffer A with 0.5 M sucrose). The nuclei and unbroken cells were pelleted by centrifugation at 500 g for 10 min. After addition of EDTA to a final concentration of 10 mM, the supernatant was centrifuged at 16 000 g for 15 min. The supernatant from this step was further centrifuged for 1 h at 100 000 g to obtain a clear cytosolic fraction. The nuclei and unbroken cell pellets were resuspended in buffer C (buffer A with 0.1% Nonidet P-40), forced through a 23-gauge needle 10 times, and centrifuged at 500 g for 10 min. This nuclear pellet was washed once with buffer C, then dissolved in lysis buffer. Lactate dehydrogenase assays were performed on both nuclei and cytosolic fractions to confirm that nuclear fractions were free of cytoplasm.
